Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INO Stock Forecast 2025-2026
$2.07
Current Price
$142.22M
Market Cap
Buy 4
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to INO Price Targets
+528.0%
To High Target of $13.00
+286.5%
To Median Target of $8.00
-13.0%
To Low Target of $1.80
INO Price Momentum
+0.5%
1 Week Change
-8.0%
1 Month Change
-50.4%
1 Year Change
+13.1%
Year-to-Date Change
-53.4%
From 52W High of $4.44
+59.2%
From 52W Low of $1.30
📊 TOP ANALYST CALLS
Did INO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inovio is one of their latest high-conviction picks.
Latest INO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, INO has a bullish consensus with a median price target of $8.00 (ranging from $1.80 to $13.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.07, the median forecast implies a 286.5% upside. This outlook is supported by 4 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jay Olson at Oppenheimer, projecting a 528.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INO Analyst Ratings
4
Buy
2
Hold
0
Sell
INO Price Target Range
Low
$1.80
Average
$8.00
High
$13.00
Current: $2.07
Latest INO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $6.00 |
| Aug 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $3.00 |
| Jul 9, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Initiates | $5.00 |
| May 14, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $13.00 |
| May 14, 2025 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $5.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $3.00 |
| Mar 19, 2025 | RBC Capital | Gregory Renza | Sector Perform | Maintains | $5.00 |
| Mar 14, 2025 | Citizens Capital Markets | Roy Buchanan | Market Outperform | Reiterates | $18.00 |
| Jan 13, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Maintains | $3.00 |
| Jan 10, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $18.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Maintains | $5.00 |
| Nov 18, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $15.00 |
| Nov 15, 2024 | RBC Capital | Gregory Renza | Sector Perform | Maintains | $6.00 |
| Oct 4, 2024 | RBC Capital | Gregory Renza | Sector Perform | Maintains | $7.00 |
| Aug 12, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $33.00 |
| Aug 9, 2024 | RBC Capital | Gregory Renza | Sector Perform | Maintains | $8.00 |
| Jul 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $15.00 |
| May 14, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Initiates | $20.00 |
| Mar 8, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $40.00 |
| Mar 7, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $11.00 |
Inovio Pharmaceuticals, Inc. (INO) Competitors
The following stocks are similar to Inovio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inovio Pharmaceuticals, Inc. (INO) Financial Data
Inovio Pharmaceuticals, Inc. has a market capitalization of $142.22M with a P/E ratio of -0.5x. The company generates $182,337 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -49,202.9% and return on equity of -328.4%.
Valuation Metrics
Market Cap
$142.22M
Enterprise Value
$70.11M
P/E Ratio
-0.5x
PEG Ratio
0.2x
Price/Sales
780.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-49,202.9%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+45.8%
Current Ratio
0.8x
Debt/Equity
-1.3x
ROE
-328.4%
ROA
-63.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inovio Pharmaceuticals, Inc. (INO) Business Model
About Inovio Pharmaceuticals, Inc.
What They Do
Develops DNA-based immunotherapies and vaccines.
Business Model
Inovio Pharmaceuticals generates revenue through the discovery, development, and commercialization of its proprietary DNA medicine platform, which focuses on immunotherapies and vaccines for infectious diseases and cancer. The company aims to enhance vaccine efficacy and expand immunotherapy applications, which may lead to partnerships, grants, and potential product sales.
Additional Information
Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio is actively working on vaccines for public health issues, including HPV-related diseases and various cancers. Its innovative approach positions it as a key player in the biotechnology industry, with a strong emphasis on addressing diseases with limited treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
134
CEO
Dr. Jacqueline E. Shea Ph.D.
Country
United States
IPO Year
1998
Website
www.inovio.comInovio Pharmaceuticals, Inc. (INO) Latest News & Analysis
Latest News
Quick Summary
Inovio Pharmaceuticals, Inc. (INO) participated in the Piper Sandler 37th Annual Healthcare Conference, highlighting its developments in the healthcare sector.
Why It Matters
Inovio Pharmaceuticals presenting at a prominent conference signals potential investor interest, updates on pipeline progress, and may influence stock performance based on market reception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
INOVIO (NASDAQ: INO) will participate in two investor conferences in December: Piper Sandler on Dec 2 and Oppenheimer on Dec 11. Management will hold one-on-one meetings with investors.
Why It Matters
INOVIO's participation in major investor conferences highlights its visibility in the biotech sector, potentially influencing stock performance and attracting investor interest in its innovative treatments.
Source: PRNewsWire
Market Sentiment:
Neutral
Inovio (INO) Upgraded to Buy: Here's Why
22 days ago
Quick Summary
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may lead to a potential rise in the stock price.
Why It Matters
Inovio's upgrade to Zacks Rank #2 signals increased earnings optimism, suggesting potential stock price appreciation and improved investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
INOVIO Pharmaceuticals announced a public offering of 13,158,000 shares at $1.90 each to support its DNA medicine development for HPV-related diseases and cancer.
Why It Matters
The pricing of a public offering can dilute existing shares and affect stock value. The focus on DNA medicines indicates potential growth in biotech, impacting investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Inovio Pharmaceuticals (INO) reported a 3Q25 GAAP EPS loss of -$0.87, missing estimates, leading to a 12% stock drop. The company has $50.8M in cash, a $25M public offering planned, and progress on INO-3107's BLA submission.
Why It Matters
Inovio's significant EPS miss and stock drop indicate financial instability, while the cash runway and public offering may suggest dilution risks. Pipeline updates hold potential but also uncertainty.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Inovio Pharmaceuticals will hold its Q3 2025 earnings call on November 10, 2025, at 4:30 PM EST, featuring key executives and analysts from various investment firms.
Why It Matters
Inovio's Q3 earnings call may reveal financial health and strategic direction, impacting stock valuation and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About INO Stock
What is Inovio Pharmaceuticals, Inc.'s (INO) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Inovio Pharmaceuticals, Inc. (INO) has a median price target of $8.00. The highest price target is $13.00 and the lowest is $1.80.
Is INO stock a good investment in 2026?
According to current analyst ratings, INO has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INO stock?
Wall Street analysts predict INO stock could reach $8.00 in the next 12 months. This represents a 286.5% increase from the current price of $2.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inovio Pharmaceuticals, Inc.'s business model?
Inovio Pharmaceuticals generates revenue through the discovery, development, and commercialization of its proprietary DNA medicine platform, which focuses on immunotherapies and vaccines for infectious diseases and cancer. The company aims to enhance vaccine efficacy and expand immunotherapy applications, which may lead to partnerships, grants, and potential product sales.
What is the highest forecasted price for INO Inovio Pharmaceuticals, Inc.?
The highest price target for INO is $13.00 from Jay Olson at Oppenheimer, which represents a 528.0% increase from the current price of $2.07.
What is the lowest forecasted price for INO Inovio Pharmaceuticals, Inc.?
The lowest price target for INO is $1.80 from at , which represents a -13.0% decrease from the current price of $2.07.
What is the overall INO consensus from analysts for Inovio Pharmaceuticals, Inc.?
The overall analyst consensus for INO is bullish. Out of 13 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are INO stock price projections?
Stock price projections, including those for Inovio Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 8:42 AM UTC